Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05488366 · ClinicalTrials.gov registry record · Early Phase 1
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
A Early Phase 1 study of Sarcoma, Soft Tissue, sponsored by University of California, Irvine.
- Active
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05488366 is a Early Phase 1 study of Sarcoma, Soft Tissue that is active but no longer recruiting, run by University of California, Irvine. The registered enrollment target is 9 participants, below the 78-participant average among 4 other Sarcoma, Soft Tissue trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05488366, a Early Phase 1 study of Sarcoma, Soft Tissue, is active but no longer recruiting, sponsored by University of California, Irvine.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma. These are subjects who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curative surgery.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Radiation therapy
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2026-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05488366
The ClinicalTrials.gov registry entry for NCT05488366 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 4 other Sarcoma, Soft Tissue trials with a reported enrollment target (88% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma, Soft Tissue appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05488366 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05488366 about?
NCT05488366 is a clinical study titled "Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma". This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma. These are subjects who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curati...
What is the current status of trial NCT05488366?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2022-08-03. Estimated completion is 2026-08.
What conditions does trial NCT05488366 study?
This clinical trial studies the following conditions: Sarcoma, Soft Tissue.
What interventions are being tested in trial NCT05488366?
The interventions under investigation include: Pembrolizumab (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT05488366?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05488366 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma, Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma
COMPLETED
-
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
COMPLETED · Phase 3
-
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.